Thyroid cancer-related bone metastases: increasingly good prospects for treatment

J. Wexler, Bone metastases from differentiated thyroid carcinoma. in Thyroid Cancer, ed. by L. Wartofsky, D. Van Nostrand (New York: Springer, 2016), pp. 723-733).. M. Schlumberger, C. Challeton, F. De Vathaire, J.P. Travagli, P. Gardet, J.D. Lumbroso, C. Francese, F. Fontaine, M. Ricard, C. Parmentier, Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J. Nucl. Med. 37, 598–605 (1996) A.C. Chiu, E.S. Delpassand, S.I. Sherman, Prognosis and treatment of brain metastases in thyroid carcinoma. J. Clin. Endocrinol. Metab. 82, 3637–3642 (1997) P. Choksi, M. Papaleontiou, C. Guo, F. Worden, M. Banerjee, M. Haymart, Skeletal complications and mortality in thyroid cancer: a population-based study. J. Clin. Endocrinol. Metab. 102, 1254–1260 (2017). https://doi.org/10.1210/jc.2016-3906 A.F. Mavrogenis, A. Angelini, C. Vottis, E. Pala, T. Calabrò, P.J. Papagelopoulos, P. Ruggieri, Modern palliative treatments for metastatic bone disease: awareness of advantages, disadvantages, and guidance. Clin. J. Pain. 32, 337–350 (2016). https://doi.org/10.1097/AJP.0000000000000255 G. Rossi, A.F. Mavrogenis, E. Rimondi, L. Braccaioli, T. Calabrò, P. Ruggieri, Selective embolization with N-butyl cyanoacrylate for metastatic bone disease. J. Vasc. Interv. Radiol. 22, 462–470 (2011). https://doi.org/10.1016/j.jvir.2010.12.023 B.H. Lang, K.P. Wong, C.Y. Cheung, K.Y. Wan, C.Y. Lo, Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis. Ann. Surg. Oncol. 4, 1329–1335 (2013). https://doi.org/10.1245/s10434-012-2711-x G. Mazziotti, A.M. Formenti, M.B. Panarotto, E. Arvat, A. Chiti, A. Cuocolo, M.E. Dottorini, C. Durante, L. Agate, S. Filetti, F. Felicetti, A. Filice, L. Pace, T. Pellegrino, M. Rodari, M. Salvatori, C. Tranfaglia, A. Versari, D. Viola, S. Frara, A. Berruti, A. Giustina, R. Giubbini, Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience. Endocrine 59, 90–101 (2018). https://doi.org/10.1007/s12020-017-1455-6 C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli, B. Caillou, M. Ricard, J.D. Lumbroso, F. De Vathaire, M. Schlumberger, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 8, 2892–2899 (2006) Z.L. Qiu, H.J. Song, Y.H. Xu, Q.Y. Luo, Efficacy and survival analysis of 131I therapy for bone metastases from differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 96, 3078–3086 (2011). https://doi.org/10.1210/jc.2011-0093 M.T. Drake, J.N. Farr, Inhibitors of sclerostin: emerging concepts. Curr. Opin. Rheumatol. 26, 447–452 (2014). https://doi.org/10.1097/BOR.0000000000000073 S. Sousa, P. Clézardin, Bone-targeted therapies in cancer-induced bone disease. Calcif. Tissue Int. 102, 227–250 (2018). https://doi.org/10.1007/s00223-017-0353-5 H. Jadvar, Targeted radionuclide therapy: An evolution toward precision cancer treatment. Ajr. Am. J. Roentgenol. 209, 277–288 (2017). https://doi.org/10.2214/AJR.17.18264